Dental benign cementomas in three horses.

Cementoma is a very rare odontogenic neoplasm of mesenchymal origin. Clinically, in 3 horses, multiple bony enlargements of the upper and lower jaw extending into the oral cavity were observed. Radiographically, multiple, well-circumscribed, radiopaque masses surrounding the roots of the upper and lower incisors or an upper premolar tooth were present. Due to malocclusion and local pain, single teeth were extracted in each case. Grossly, a hard grayish-white mass surrounding the root of the incisors and the premolars was identified. Histopathologically, the tumors consisted of excessive deposition of cementum-like tissue. Cells, resembling cementoblasts, lined irregularly shaped lacunae, which were present in the tumor tissue, and showed minimal cellular pleomorphism. Mitotic figures were not present. Macroscopically and histologically, all 3 equine cases displayed great similarities to cementomas in other species. However, due to their high degree of differentiation, hypercementosis must be considered as a differential diagnosis.

[Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma]. / Anderung des spezifischen Atemwegswiderstandes (sRaw) nach Pulverinhalation von Formoterol oder Salmeterol bei mittelschwerem Asthma bronchiale.

Formoterol and salmeterol are two long acting beta 2 agonists available for the treatment of asthma which show differences in onset of action. In a multicentre parallel group study, patients with moderate asthma were investigated by measuring the specific airway resistance (sRaw), a more sensitive parameter than FEV1. A total of 99 patients were randomised for open treatment with either 12 micrograms formoterol delivered via Turbohaler or 50 micrograms salmeterol via Diskus. The patients were between 18 and 66 years of age, had a medium FEV1 of 68.8% (+/- 17.8%) predicted and showed a medium reversibility of 28.8% (+/- 16.5%). The patients response to one inhalation of the study drug was investigated by sRaw measurements 2, 5, 10, 20 and 60 minutes after inhalation of the formulation. Additionally, FEV1 was measured. The results show a significant decrease in specific airway resistance of 29% within the first two minutes in patients who had received 12 micrograms formoterol via Turbohaler. However, patients on salmeterol showed no change (sRaw +/- 1%). This difference is statistically highly significant (p < 0.0001). Furthermore, in 49% of the patients treated with salmeterol an increase in sRaw was seen immediately after inhalation of the drug. This increase was +16.4% in an average of 2 minutes after inhalation. One hour after inhalation the differences between the groups were small and not significant neither between formoterol and salmeterol-treated patients nor within the salmeterol group. In the following week patients were treated with 12 micrograms formoterol Turbohaler b.i.d. or 50 micrograms salmeterol Diskus b.i.d., respectively. A further sRaw measurement was performed 11 +/- 1 hours after the last inhalation of the drug. The results for sRaw and FEV1 show no differences between both study drugs indicating a similar duration of action for both formoterol Turbohaler and Salmeterol Diskus in moderate asthma. No serious adverse events were reported. The adverse event profile observed in both study groups was comparable. Thus, this study shows once again that formoterol delivered via Turbohaler has a more rapid onset of bronchodilating action compared with salmeterol Diskus. Furthermore the inhalation of salmeterol via Diskus in one-half of the patients led to an increase in specific airway resistance within the first minutes after inhalation. It is worth discussing whether an unspecific reaction to the relatively large lactose particles which are components of the salmeterol Diskus formulation are responsible for this observation.

[Modification of nonspecific bronchial hyperreactivity to cold air hyperventilation and carbachol by nedocromil and budesonide]. / Beeinflussung der unspezifischen bronchialen Hyperreagibilität auf Kaltlufthyperventilation und Carbachol durch Nedrocromil und Budenosid.

In a double blind crossover trial we compared the effect of a four week treatment with inhaled nedocromil (4 x 4 mg/d) or budesonide (2 x 400 micrograms/d by spacer) on non-specific bronchial hyperresponsiveness (BHR) to cold air hyperventilation (CHV) and carbachol. 15 persons with clinically mild asthma, who showed a more than 50% decrease in sG(aw) after CHV were randomly allocated to treatment groups. A double dummy technique was applied. Before and after both treatment periods, which were separated by an out wash period of four weeks, BHR to isocapnic cold air hyperventilation and carbachol was determined on two consecutive days. 13 persons completed the study. Maximum percentual drop of sG(aw-) and FEV1-values after CHV, the number of steps of carbachol-provocation carried out to reach a decrease in sGaw of at least 50% and the calculated cumulative breath units (CBU) of carbachol to cause a 50% (20%) decrease in sG(aw) (FEV1) were assessed. Peak-flow values were registered throughout the study. Data were compared by means of Wilcoxon's matched-pairs signed-ranks test. After budesonide most parameter showed a significant decrease of BHR (CHV: sG(aw) p < 0.1; FEV1 p < 0.05; Carbachol: provocation-steps: p < 0.05; CBU: PD50 sG(aw) p < 0.05; PD20 FEV1 p < 0.05). There was no evidence for an influence of nedocromil on BHR (p-values all > 0.2). Comparing both treatments there was a difference in favour of budesonide partly reaching significance at 5% level. Budesonide but not nedocromil treatment showed a significant increase in peak-flow values (morning p < 0.02, evening p < 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Preparation of fish protein isolate and hydrolyzate (Mugil cephalus) and their incorporation into Mexican foods.

Fish protein isolates (FPI) and hydrolyzates (FPH) were obtained from mullet (Mugil cephalus) through alkali solubilization and HCl precipitation for FPI, as well as enzymatic hydrolysis for FPH. The powdered products showed solubilities of 50 and 89%, and emulsifying capacities of 36 and 39 ml oil/100 mg for FPI and FPH, respectively, with protein contents of 90% and oil contents lower than 1.6%. Both products were used to enrich cereals and legumes in order to increase their protein content and quality. The resulting mixtures were used to prepare common Mexican dishes. When up to 20 and 35% of the total protein was provided by FPI and FPH, respectively, the dishes were well accepted by 70% of the panel.

[The lung in heart diseases]. / Die Lunge bei Herzerkrankungen.

The effects of "hypocirculation" and "hypercirculation" of the lungs are small. Hypocirculation has an influence of the ventilation/perfusion ratio, and can thus contribute to hypocapnia. In the early stages, hypercirculation--in particular via a left-to-right shung, leads to an increase in diffusion capacity; after a course of many years, a "counter-situation" occurs. Progressive pulmonary hypertension, as is exemplified for mitral stenosis, leads to measurable restrictive and obstructive impairment of function, and possible to unspecific hyper-reaction, as also, over the long-term, to a diminishement in membrane diffusion capacity. Chronic left heart failure is characterised by interstitial oedema at the level of the alveolar and bronchial capillary beds. The results are measurable restrictions in the static volumes, and in particular of the obstruction parameters and the closing volume that involve the small airways. In the individual case, no statement as to the extent of left heart failure is possible. In the passive pulmonary hypertension phase, diffusion capacity increases; in the further course of the disease, with development of interstitial and alveolar oedema, it decreases again. In acute left heart failure, the persistance and/or extent of pulmonary oedema is not determined solely by the magnitude of the pulmonary venous pressure. Permeability oedema--brought about by mediators--would appear to be significant on the basis of animal experiments. Not infrequently, left cardiac failure leads to small pleural effusions which occur in combination with substantial atelectasia, the aetiology of which is unclear. Interpretation difficulties are caused by the clinical findings and function-analytical data obtained in patients with a combination of chronic lung disease and reducted volume storage capacity of the pulmonary circulation and of the left heart failure, a common situation in the elderly patient. Diminished pulmonary function parameters that fail to adequate respond to bronchodilators may be an expression of left ventricular failure.

[Alveolitis after inhalation of leather-impregnation spray (author's transl)]. / Alveolitis nach Lederspray-Inhalation.

After inhalation of leather-impregnation sprays in a confined space five patients developed acute and severe symptoms of alveolitis, with disorders of ventilation and diffusion as well as marked radiological changes. In one case without any treatment pulmonary fibrosis developed. In the other four immediate administrations of steroids produced complete healing. Inhalation of small amounts of leather-impregnation spray produced no changes in pulmonary function tests in volunteers. There were no similarities with forms of alveolitis produced by other noxious inhalation agents.